Rapamycin Modulates Glucocorticoid Receptor Function, Blocks Atrophogene REDD1, and Protects Skin from Steroid Atrophy

Ekaterina Lesovaya, Shivani Agarwal, Benjamin Readhead, Elena Vinokour, Gleb Baida, Pankaj Bhalla, Kirill Kirsanov, Marianna Yakubovskaya, Leonidas C. Platanias, Joel T. Dudley, Irina Budunova

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Glucocorticoids have excellent therapeutic properties; however, they cause significant adverse atrophogenic effects. The mTORC1 inhibitor REDD1 has been recently identified as a key mediator of glucocorticoid-induced atrophy. We performed computational screening of a connectivity map database to identify putative REDD1 inhibitors. The top selected candidates included rapamycin, which was unexpected because it inhibits pro-proliferative mTOR signaling. Indeed, rapamycin inhibited REDD1 induction by glucocorticoids dexamethasone, clobetasol propionate, and fluocinolone acetonide in keratinocytes, lymphoid cells, and mouse skin. We also showed blunting of glucocorticoid-induced REDD1 induction by either catalytic inhibitor of mTORC1/2 (OSI-027) or genetic inhibition of mTORC1, highlighting role of mTOR in glucocorticoid receptor signaling. Moreover, rapamycin inhibited glucocorticoid receptor phosphorylation, nuclear translocation, and loading on glucocorticoid-responsive elements in REDD1 promoter. Using microarrays, we quantified a global effect of rapamycin on gene expression regulation by fluocinolone acetonide in human keratinocytes. Rapamycin inhibited activation of glucocorticoid receptor target genes yet enhanced the repression of pro-proliferative and proinflammatory genes. Remarkably, rapamycin protected skin against glucocorticoid-induced atrophy but had no effect on the glucocorticoid anti-inflammatory activity in different in vivo models, suggesting the clinical potential of combining rapamycin with glucocorticoids for the treatment of inflammatory diseases.

Original languageEnglish (US)
Pages (from-to)1935-1944
Number of pages10
JournalJournal of Investigative Dermatology
Volume138
Issue number9
DOIs
StatePublished - Sep 1 2018
Externally publishedYes

Fingerprint

Glucocorticoid Receptors
Sirolimus
Glucocorticoids
Atrophy
Skin
Steroids
Fluocinolone Acetonide
Keratinocytes
Gene expression regulation
Genes
Clobetasol
Phosphorylation
Gene Expression Regulation
Microarrays
Dexamethasone
Screening
Anti-Inflammatory Agents
Chemical activation
Databases
Lymphocytes

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Dermatology
  • Cell Biology

Cite this

Rapamycin Modulates Glucocorticoid Receptor Function, Blocks Atrophogene REDD1, and Protects Skin from Steroid Atrophy. / Lesovaya, Ekaterina; Agarwal, Shivani; Readhead, Benjamin; Vinokour, Elena; Baida, Gleb; Bhalla, Pankaj; Kirsanov, Kirill; Yakubovskaya, Marianna; Platanias, Leonidas C.; Dudley, Joel T.; Budunova, Irina.

In: Journal of Investigative Dermatology, Vol. 138, No. 9, 01.09.2018, p. 1935-1944.

Research output: Contribution to journalArticle

Lesovaya, E, Agarwal, S, Readhead, B, Vinokour, E, Baida, G, Bhalla, P, Kirsanov, K, Yakubovskaya, M, Platanias, LC, Dudley, JT & Budunova, I 2018, 'Rapamycin Modulates Glucocorticoid Receptor Function, Blocks Atrophogene REDD1, and Protects Skin from Steroid Atrophy', Journal of Investigative Dermatology, vol. 138, no. 9, pp. 1935-1944. https://doi.org/10.1016/j.jid.2018.02.045
Lesovaya, Ekaterina ; Agarwal, Shivani ; Readhead, Benjamin ; Vinokour, Elena ; Baida, Gleb ; Bhalla, Pankaj ; Kirsanov, Kirill ; Yakubovskaya, Marianna ; Platanias, Leonidas C. ; Dudley, Joel T. ; Budunova, Irina. / Rapamycin Modulates Glucocorticoid Receptor Function, Blocks Atrophogene REDD1, and Protects Skin from Steroid Atrophy. In: Journal of Investigative Dermatology. 2018 ; Vol. 138, No. 9. pp. 1935-1944.
@article{72299a81d09e4b2aacb2de347ba8c2c0,
title = "Rapamycin Modulates Glucocorticoid Receptor Function, Blocks Atrophogene REDD1, and Protects Skin from Steroid Atrophy",
abstract = "Glucocorticoids have excellent therapeutic properties; however, they cause significant adverse atrophogenic effects. The mTORC1 inhibitor REDD1 has been recently identified as a key mediator of glucocorticoid-induced atrophy. We performed computational screening of a connectivity map database to identify putative REDD1 inhibitors. The top selected candidates included rapamycin, which was unexpected because it inhibits pro-proliferative mTOR signaling. Indeed, rapamycin inhibited REDD1 induction by glucocorticoids dexamethasone, clobetasol propionate, and fluocinolone acetonide in keratinocytes, lymphoid cells, and mouse skin. We also showed blunting of glucocorticoid-induced REDD1 induction by either catalytic inhibitor of mTORC1/2 (OSI-027) or genetic inhibition of mTORC1, highlighting role of mTOR in glucocorticoid receptor signaling. Moreover, rapamycin inhibited glucocorticoid receptor phosphorylation, nuclear translocation, and loading on glucocorticoid-responsive elements in REDD1 promoter. Using microarrays, we quantified a global effect of rapamycin on gene expression regulation by fluocinolone acetonide in human keratinocytes. Rapamycin inhibited activation of glucocorticoid receptor target genes yet enhanced the repression of pro-proliferative and proinflammatory genes. Remarkably, rapamycin protected skin against glucocorticoid-induced atrophy but had no effect on the glucocorticoid anti-inflammatory activity in different in vivo models, suggesting the clinical potential of combining rapamycin with glucocorticoids for the treatment of inflammatory diseases.",
author = "Ekaterina Lesovaya and Shivani Agarwal and Benjamin Readhead and Elena Vinokour and Gleb Baida and Pankaj Bhalla and Kirill Kirsanov and Marianna Yakubovskaya and Platanias, {Leonidas C.} and Dudley, {Joel T.} and Irina Budunova",
year = "2018",
month = "9",
day = "1",
doi = "10.1016/j.jid.2018.02.045",
language = "English (US)",
volume = "138",
pages = "1935--1944",
journal = "Journal of Investigative Dermatology",
issn = "0022-202X",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Rapamycin Modulates Glucocorticoid Receptor Function, Blocks Atrophogene REDD1, and Protects Skin from Steroid Atrophy

AU - Lesovaya, Ekaterina

AU - Agarwal, Shivani

AU - Readhead, Benjamin

AU - Vinokour, Elena

AU - Baida, Gleb

AU - Bhalla, Pankaj

AU - Kirsanov, Kirill

AU - Yakubovskaya, Marianna

AU - Platanias, Leonidas C.

AU - Dudley, Joel T.

AU - Budunova, Irina

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Glucocorticoids have excellent therapeutic properties; however, they cause significant adverse atrophogenic effects. The mTORC1 inhibitor REDD1 has been recently identified as a key mediator of glucocorticoid-induced atrophy. We performed computational screening of a connectivity map database to identify putative REDD1 inhibitors. The top selected candidates included rapamycin, which was unexpected because it inhibits pro-proliferative mTOR signaling. Indeed, rapamycin inhibited REDD1 induction by glucocorticoids dexamethasone, clobetasol propionate, and fluocinolone acetonide in keratinocytes, lymphoid cells, and mouse skin. We also showed blunting of glucocorticoid-induced REDD1 induction by either catalytic inhibitor of mTORC1/2 (OSI-027) or genetic inhibition of mTORC1, highlighting role of mTOR in glucocorticoid receptor signaling. Moreover, rapamycin inhibited glucocorticoid receptor phosphorylation, nuclear translocation, and loading on glucocorticoid-responsive elements in REDD1 promoter. Using microarrays, we quantified a global effect of rapamycin on gene expression regulation by fluocinolone acetonide in human keratinocytes. Rapamycin inhibited activation of glucocorticoid receptor target genes yet enhanced the repression of pro-proliferative and proinflammatory genes. Remarkably, rapamycin protected skin against glucocorticoid-induced atrophy but had no effect on the glucocorticoid anti-inflammatory activity in different in vivo models, suggesting the clinical potential of combining rapamycin with glucocorticoids for the treatment of inflammatory diseases.

AB - Glucocorticoids have excellent therapeutic properties; however, they cause significant adverse atrophogenic effects. The mTORC1 inhibitor REDD1 has been recently identified as a key mediator of glucocorticoid-induced atrophy. We performed computational screening of a connectivity map database to identify putative REDD1 inhibitors. The top selected candidates included rapamycin, which was unexpected because it inhibits pro-proliferative mTOR signaling. Indeed, rapamycin inhibited REDD1 induction by glucocorticoids dexamethasone, clobetasol propionate, and fluocinolone acetonide in keratinocytes, lymphoid cells, and mouse skin. We also showed blunting of glucocorticoid-induced REDD1 induction by either catalytic inhibitor of mTORC1/2 (OSI-027) or genetic inhibition of mTORC1, highlighting role of mTOR in glucocorticoid receptor signaling. Moreover, rapamycin inhibited glucocorticoid receptor phosphorylation, nuclear translocation, and loading on glucocorticoid-responsive elements in REDD1 promoter. Using microarrays, we quantified a global effect of rapamycin on gene expression regulation by fluocinolone acetonide in human keratinocytes. Rapamycin inhibited activation of glucocorticoid receptor target genes yet enhanced the repression of pro-proliferative and proinflammatory genes. Remarkably, rapamycin protected skin against glucocorticoid-induced atrophy but had no effect on the glucocorticoid anti-inflammatory activity in different in vivo models, suggesting the clinical potential of combining rapamycin with glucocorticoids for the treatment of inflammatory diseases.

UR - http://www.scopus.com/inward/record.url?scp=85048460617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048460617&partnerID=8YFLogxK

U2 - 10.1016/j.jid.2018.02.045

DO - 10.1016/j.jid.2018.02.045

M3 - Article

VL - 138

SP - 1935

EP - 1944

JO - Journal of Investigative Dermatology

JF - Journal of Investigative Dermatology

SN - 0022-202X

IS - 9

ER -